Bioequivalence Study of Clobetasol Propionate 0.5 mg/g Ointments in Localized Therapy-Resistant Inflammatory Skin Diseases in Healthy Adults

The primary objective of this study is to evaluate the **bioequivalence** of two clobetasol propionate 0.5 mg/g ointments through a vasoconstriction assay following topical application in healthy adult subjects. This is clinically relevant as clobetasol propionate is a potent topical corticosteroid used in the management of localized, therapy-resistant inflammatory skin diseases. Establishing bioequivalence ensures that the two formulations have similar efficacy and safety profiles, which is crucial for therapeutic consistency and patient outcomes.

The clinical trial involves participants with **localized, therapy-resistant inflammatory skin diseases** for which the use of topical corticosteroids with very high potency is indicated. The study population includes both male and female subjects, with an age range starting from 3 years old. The trial also considers a vulnerable population. However, the sponsor has not provided information regarding the total number of participants. The selection of the trial population is based on specific criteria related to the medical condition, but detailed inclusion or exclusion criteria have not been disclosed. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, are not specified in the available data.

The clinical trial is designed to evaluate the **bioequivalence** of two clobetasol propionate 0.5 mg/g ointments through a vasoconstriction study in healthy adult human subjects. The trial is structured as a Phase 2 study, with a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is July 24, 2023, with an anticipated end date of November 21, 2023, indicating a total trial duration of approximately four months.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following the screening, participants will attend multiple follow-up visits, where the application of the ointments and subsequent assessments will be conducted to monitor the vasoconstriction response. The end-of-study visit will conclude the trial, during which final evaluations and data collection will occur to assess the primary and secondary endpoints.

The expected length of participant involvement spans the entire trial duration, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with study protocols, adverse reactions to the ointments, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the efficacy and safety of the ointments for treating localized, therapy-resistant inflammatory skin diseases, where the use of topical corticosteroids with very high potency is indicated.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on July 24, 2023, with an estimated end date of November 21, 2023. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will proceed according to the standard protocols for Phase 2 studies, focusing on the assessment of efficacy in the context of the disease under investigation. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.